QR код

MET Amplification and Efficacy of Nivolumab in Patients With NSCLC

Introduction: MET amplification is an important genetic alteration in NSCLC. Unlike in patients with EGFR and ALK alterations, the efficacy of immune checkpoint inhibitors in patients with MET-amplified NSCLC remains unknown. Methods: An exploratory analysis of a prospective, multi-institutional coh...

Повний опис

Збережено в:
Автори: Katsuhiro Yoshimura, MD, PhD, Yusuke Inoue, MD, PhD, Naoki Inui, MD, PhD, Masato Karayama, MD, PhD, Hideki Yasui, MD, PhD, Hironao Hozumi, MD, PhD, Yuzo Suzuki, MD, PhD, Kazuki Furuhashi, MD, PhD, Tomoyuki Fujisawa, MD, PhD, Noriyuki Enomoto, MD, PhD, Yutaro Nakamura, MD, PhD, Haruhiko Sugimura, MD, PhD, Takafumi Suda, MD, PhD
Формат: Artigo
Мова:Inglês
Опубліковано: Elsevier 2021-11-01
Серія:JTO Clinical and Research Reports
Предмети:
Lung cancer
MET
Nivolumab
Amplification
Immune checkpoint inhibitor
Онлайн доступ:http://www.sciencedirect.com/science/article/pii/S2666364321000989
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси